Novo Nordisk Balance Sheet Health
Financial Health criteria checks 4/6
Novo Nordisk has a total shareholder equity of DKK120.5B and total debt of DKK57.0B, which brings its debt-to-equity ratio to 47.3%. Its total assets and total liabilities are DKK397.4B and DKK276.9B respectively. Novo Nordisk's EBIT is DKK125.5B making its interest coverage ratio -275.2. It has cash and short-term investments of DKK74.9B.
Key information
47.3%
Debt to equity ratio
DKK 56.97b
Debt
| Interest coverage ratio | -275.2x |
| Cash | DKK 74.88b |
| Equity | DKK 120.52b |
| Total liabilities | DKK 276.92b |
| Total assets | DKK 397.44b |
Recent financial health updates
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?
Jul 27
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?
Apr 14Recent updates
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)
Nov 13Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 09Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?
Nov 01Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable
Oct 09Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?
Jul 27Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?
Jul 05A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)
Jun 09Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations
May 09Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts
May 04The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)
Apr 28Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?
Apr 14Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?
Mar 18Novo Nordisk A/S' (CPH:NOVO B) Price In Tune With Earnings
Dec 30Financial Position Analysis
Short Term Liabilities: NOVO B's short term assets (DKK195.2B) do not cover its short term liabilities (DKK208.4B).
Long Term Liabilities: NOVO B's short term assets (DKK195.2B) exceed its long term liabilities (DKK68.6B).
Debt to Equity History and Analysis
Debt Level: NOVO B has more cash than its total debt.
Reducing Debt: NOVO B's debt to equity ratio has increased from 8.2% to 47.3% over the past 5 years.
Debt Coverage: NOVO B's debt is well covered by operating cash flow (207.5%).
Interest Coverage: NOVO B earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 00:35 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novo Nordisk A/S is covered by 71 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |